Home > Boards > US OTC > Miscellaneous >

Therapeutic Solutions International, Inc. (TSOI)

TSOI RSS Feed
Add TSOI Price Alert      Hide Sticky   Hide Intro
Moderator: gotinearly, subslover, centsability4me, CrazyKar123, TruthFairy222
Search This Board: 
Last Post: 10/21/2019 9:59:46 AM - Followers: 199 - Board type: Free - Posts Today: 3

 

Image result for Therapeutic Solutions International

Image may contain: indoor
More lab photos posted here on 10/11/19 : https://www.facebook.com/pg/tsoihome/photos/?ref=page_internal

Therapeutic Solutions International Develops Glucoraphanin + NanoStilbene Encapsulated product for reduction of Prostate Specific Antigen (PSA) called NanoPSA.
https://mynanostilbene.com/?page_id=517

NanoPSA is a blend of NanoStilbene™ and Broccoli Sprout Extract (BSE) providing 74mg of BSE and 125mg of our patented NanoStilbene, a proprietray formulation of nanoparticle pterostilbene.

BSE contains the compound known as glucoraphanin. Glucoraphanin converts into a new compound in the intestine, known as sulforaphane (SFN). SFN promotes Phase II detox processes to assist in the removal of toxins from your body.

Because we rely upon the gut for the conversion of BSE into SFN we added NanoStilbene which causes beneficial changes in microbiota composition, and improved metabolic function.

Antioxidants protect the cells in our body from damage that is cause caused by excessive oxidative stress, in the form of free radicals, defined as unstable compounds missing an electron [1]. Documented evidence shows the most available source of electrons is our healthy cells. Given sufficient time and the persistent exposure of our healthy cell walls to free radicals eventually breaks them down, leading to a reduction in good health.

Antioxidants are self-sacrificing electron donors and function by giving free radicals another source of electrons instead of healthy cell walls. When antioxidants donate their electrons to free radicals it results in the neutralization of them which prevents them from appropriating any more electrons leading to even more damage. Antioxidants can help prevent or minimize the build-up of damage over time.

Free radical damage has been closely linked with inflammation because the body interprets oxidative damage as an overall threat [2]. We know what the result is, a cycle of oxidation: damage – immune cells – more damage. Increasing antioxidant potential in the body provides a solution by helping to prevent a lot of oxidative damage in the first place.

By eating foods that contain antioxidants like Vitamins C & E [3,4] we can generally remove free radicals before they start causing damage and powerful antioxidants like pterostilbene can be very beneficial [5].

There are also what we know as the indirect antioxidants and enzymes produced by our bodies like glutathione and superoxide dismutase [6,7,8].

This leads to a system in place known as Phase II detoxification that allows for increases of antioxidant enzymes by consuming glucoraphanin, a potent activator of Phase II detox [9,10,11].

Glucoraphanin was first discovered in the 1990’s [12,13]. Like pterostilbene and resveratrol, glucoraphanin works in a plant’s defense system in a similar way [14,15,16].

Glucoraphanin, being a glucosinolate that can be found in broccoli is converted into its bioactive form called sulforaphane.

The conversion into sulforaphane is caused by an enzyme called myrosinase. In the absence of myrosinase its very interesting that the body’s gut microflora will perform the conversion [17].

Glucoraphanin then is the precursor to sulforaphane [18,19]. Glucoraphanin is one of a few molecules known as isothiocyanates, existing mainly in cruciferous vegetables like broccoli.

Sulforaphane appears to act on the prototypical anti-inflammatory mechanism of inhibiting NFkB translocation, a mechanism which disrupts inflammatory signals to the nucleus [20].

In a study using Macrophages LPS-induced inflammation (Lipopolysaccharide-Induced Inflammation ) was decreased with sulforaphane by inhibiting NO release, TNF-a release, and PGE2 production [20].

The mechanism of sulforaphane inhibiting NF-kB translocation does not appear to be via directly influencing the inhibitory unit I?B-ß [21,22]) but instead reduces the production of I?B-a. Sulforaphane may also directly prevent NF-kB from forming complexes when in the nucleus[20].

Anti-inflammatory effects of Sulforaphane are mediated by preventing NF-kB from translocating to the nucleus, which disrupts pro-inflammatory signals from acting in the nucleus.

Sulforaphane appears to be an inhibitor of thioredoxin reductase in LPS-stimulated macrophages, which may be upstream of its effects on NF-kB [21] as thioredoxin may increase NF-kB activity in pro-inflammatory conditions [22]. Sulforaphane appears to be synergistic in this regard with the agent CDNB,[21] an irreversible thioredoxin reductase inactivator [23].

In non-immune cells not stimulated with LPS, thioredoxin can be increased secondary to activation of the anti-oxidant response element (ARE) from Nrf2 activation; induction of thioredoxin has been seen with injections of 0.5mg/kg sulforaphane (physiologically relevant concentrations) [24]. Thioredoxin reductase is also a molecular target of pyrroloquinoline quinone, but interactions with Sulforaphane are unknown.

Some cross-over from Sulforaphane’s antioxidant actions may influence inflammatory properties due to some proteins that act in both pathways.

For example, in rheumatoid arthritis, characterized by inflammation and rapidly proliferating synoviocytes, (which is commonly seen as a treatment target [25] sulforaphane appears to be able to, in vitro in cultured synoviocytes, suppress TNF-a induced inflammation and proliferation when preincubated (secondary to activating Nrf2) and induce apoptosis in cultures already stimulated with TNF-a [26].

In cancer, sulforaphane appears to act as a Histone Deacetylase inhibitor, a mechanism that can induce expression of p21Cip1/Waf1 via deacetylating histones H3 and H4 [27,28]. The potency of sulforaphane at 15uM appears to be as effective as the standard drug trichostatin A at 100ng/mL, with additive benefits when both were coincubated;[28] as they do not influence Histone Deacetylase protein content nor ß-catenin (content or translocation), it appears they work by depressing the TOPflash promoter resulting in up to a doubling of acetylation as measured by histone H3 and H4 28]. Sulforaphane itself does not work in this regard, but appears to work via metabolites, with sulforaphane-cysteine and sulforaphane-NAC being effective in a concentration dependent manner [28].

NanoPSA - a blend of NanoStilbene™ and Broccoli Sprout Extract (BSE)

Therapeutic Solutions International Develops Glucoraphanin + NanoStilbene Encapsulated product for reduction of Prostate Specific Antigen (PSA) called NanoPSA.

Antioxidants protect the cells in our body from damage that is cause caused by excessive oxidative stress, in the form of free radicals, defined as unstable compounds missing an electron [1]. Documented evidence shows the most available source of electrons is our healthy cells. Given sufficient time and the persistent exposure of our healthy cell walls to free radicals eventually breaks them down, leading to a reduction in good health.

Antioxidants are self-sacrificing electron donors and function by giving free radicals another source of electrons instead of healthy cell walls. When antioxidants donate their electrons to free radicals it results in the neutralization of them which prevents them from appropriating any more electrons leading to even more damage. Antioxidants can help prevent or minimize the build-up of damage over time.

Free radical damage has been closely linked with inflammation because the body interprets oxidative damage as an overall threat [2]. We know what the result is, a cycle of oxidation: damage – immune cells – more damage. Increasing antioxidant potential in the body provides a solution by helping to prevent a lot of oxidative damage in the first place.

By eating foods that contain antioxidants like Vitamins C & E [3,4] we can generally remove free radicals before they start causing damage and powerful antioxidants like pterostilbene can be very beneficial [5].

There are also what we know as the indirect antioxidants and enzymes produced by our bodies like glutathione and superoxide dismutase [6,7,8].

This leads to a system in place known as Phase II detoxification that allows for increases of antioxidant enzymes by consuming glucoraphanin, a potent activator of Phase II detox [9,10,11].

Glucoraphanin was first discovered in the 1990’s [12,13]. Like pterostilbene and resveratrol, glucoraphanin works in a plant’s defense system in a similar way [14,15,16].

Glucoraphanin, being a glucosinolate that can be found in broccoli is converted into its bioactive form called sulforaphane.

The conversion into sulforaphane is caused by an enzyme called myrosinase. In the absence of myrosinase its very interesting that the body’s gut microflora will perform the conversion [17].

Glucoraphanin then is the precursor to sulforaphane [18,19]. Glucoraphanin is one of a few molecules known as isothiocyanates, existing mainly in cruciferous vegetables like broccoli.

Sulforaphane appears to act on the prototypical anti-inflammatory mechanism of inhibiting NFkB translocation, a mechanism which disrupts inflammatory signals to the nucleus [20].

In a study using Macrophages LPS-induced inflammation (Lipopolysaccharide-Induced Inflammation ) was decreased with sulforaphane by inhibiting NO release, TNF-a release, and PGE2 production [20].

The mechanism of sulforaphane inhibiting NF-kB translocation does not appear to be via directly influencing the inhibitory unit I?B-ß [21,22]) but instead reduces the production of I?B-a. Sulforaphane may also directly prevent NF-kB from forming complexes when in the nucleus[20].

Anti-inflammatory effects of Sulforaphane are mediated by preventing NF-kB from translocating to the nucleus, which disrupts pro-inflammatory signals from acting in the nucleus.

Sulforaphane appears to be an inhibitor of thioredoxin reductase in LPS-stimulated macrophages, which may be upstream of its effects on NF-kB [21] as thioredoxin may increase NF-kB activity in pro-inflammatory conditions [22]. Sulforaphane appears to be synergistic in this regard with the agent CDNB,[21] an irreversible thioredoxin reductase inactivator [23].

In non-immune cells not stimulated with LPS, thioredoxin can be increased secondary to activation of the anti-oxidant response element (ARE) from Nrf2 activation; induction of thioredoxin has been seen with injections of 0.5mg/kg sulforaphane (physiologically relevant concentrations) [24]. Thioredoxin reductase is also a molecular target of pyrroloquinoline quinone, but interactions with Sulforaphane are unknown.

Some cross-over from Sulforaphane’s antioxidant actions may influence inflammatory properties due to some proteins that act in both pathways.

For example, in rheumatoid arthritis, characterized by inflammation and rapidly proliferating synoviocytes, (which is commonly seen as a treatment target [25] sulforaphane appears to be able to, in vitro in cultured synoviocytes, suppress TNF-a induced inflammation and proliferation when preincubated (secondary to activating Nrf2) and induce apoptosis in cultures already stimulated with TNF-a [26].

In cancer, sulforaphane appears to act as a Histone Deacetylase inhibitor, a mechanism that can induce expression of p21Cip1/Waf1 via deacetylating histones H3 and H4 [27,28]. The potency of sulforaphane at 15uM appears to be as effective as the standard drug trichostatin A at 100ng/mL, with additive benefits when both were coincubated;[28] as they do not influence Histone Deacetylase protein content nor ß-catenin (content or translocation), it appears they work by depressing the TOPflash promoter resulting in up to a doubling of acetylation as measured by histone H3 and H4 28]. Sulforaphane itself does not work in this regard, but appears to work via metabolites, with sulforaphane-cysteine and sulforaphane-NAC being effective in a concentration dependent manner [28].

Prostate Cancer:

Oral administration of Sulforaphane can reach the prostate at concentrations between 0.07-0.1mg/g wet weight between 2-6 hours after ingestion of (human dose equivalent extrapolated from mice) 1.55-6.2mg/kg; although in a manner that does not correlate with serum values [29].

Sulforaphane is able to release free hydrogen sulfide (H2S) in prostatic cancer cells, and 5-50µM sulforaphane causes concentration dependent H2S release (via cystathionine ?-lyase) and reductions in cellular viability in a manner that is partially blocked by scavenging H2S [30]. H2S, as well as sulforaphane, activated all three major MAPKs (ERK, JNK, p38) and inhibiting the activation of these MAPKs blocked the effects of H2S [30].

Histone deacetylase 6 (HDAC6) is a protein that appears to disrupt a cytoplasmic chaperone called HSP90,[31] and this disruption dysregulates the androgen receptor and attenuates signaling through the androgen receptor at 10-20µM concentration;[32] this is mediated via HSP90 hyperacetylation from inhibiting HDAC6 [33]. Transcriptional activity was not ablated with sulforaphane, indicating that inhibition came post-transcription and was thought to be through a reduction in Androgen Receptor content in both LNCaP and VCaP prostatic cancer cell lines,[32] as well as BPH-1 and PC-3 cells[34] most of which mimick the elevation of androgen receptor during prostate cancer [35].

Interestingly, there is a synthetic analogue of Sulforaphane called D,L-Sulforaphane that is currently being investigated for its usage against prostate cancers; which appears to be promising [36,37].

Possibly secondary to these mechanisms, Sulforaphane has been found to inhibit cancerous cell growth and induce apoptosis of cancer cells in vitro [38].

One study assessing possible nutrient interactions noted, with curcumin and EGCG form green tea catechins tested in LNCaP cells alongside Sulforaphane, that pairing either of two nutraceuticals with Sulforaphane showed efficacy in reducing cell proliferation relative to control and combining all three trended to be more significant [39].

Interactions:

In response to oral sulforaphane, kidney concentrations of sulforaphane appear to range from 0.06-0.07mg/g wet weight between 4-6 hours after ingestion; suggesting that oral supplementation can load in the kidneys [40] and appears to be an effective kidney protective compound during periods of toxin or physical stressors to the kidneys, with protection only existing during periods of Sulforaphane consumption.

Sulforaphane, at an oral dose of 0.5mg/kg bodyweight in mice for 3 months, was able to significantly attenuate the progression of renal disease (as assessed by kidney weight the albumin:creatinine ratio, normalizing the difference between diabetic and control mice by 41% and 37.7% respectively) in diabetic mice only when it was being consumed; with benefits ceasing upon cessation of Sulforaphane [41]. These effects were mediated by Nrf2 activation preventing oxidative and inflammatory stressors,[41] which also appears to underlie protection of the kidneys from organotoxins (with similar potency as curcumin),[42] unilateral ureteral obstruction,[43] diabetic nephropathy,[41,44] ischemia/reperfusion,[45] and cisplatin [46].

In the liver there is one study using streptozotocin to induce type 1 diabetes noted that sulforaphane at 0.05-0.5mg/kg of the diet prior to injections exacerbated some damage to the liver, increasing AST (but not ALT) and total cholesterol (but not HDL-C nor hepatic Triglycerides; serum TGs was beneficially reduced to control levels) [47].

Synergistic Benefits of Co-Compounds:

Curcumin:


Sulforaphane appears to be synergistic with Curcumin in regard to anti-inflammatory actions in Macrophages, as the level of anti-inflammatory effects exerted by either alone is matched by their combination when concentrations are dropped to 40% [48]. This synergism is not at the level of proinflammatory mRNA induction, but rather at the level of inducing antioxidative protein mRNA of HO-1 and NQO1 [48]. One other study measuring apoptosis in pancreatic cancer cells (PaCa-2 and Panc-1) in vitro noted synergism with Sulforaphane, Curcumin, and Aspirin when at 5uM, 2.5uM, and 25uM; respectively.[49]

Phenethyl Isothiocyanate:

Phenethyl Isothiocyanate (PEITC) is another compound found in Brassica vegetables alongside Diindolylmethane and Sulforaphane (SFN) and appears to be synergistic with the latter. In a study on cultured macrophages (RAW 264.7, immune cells) it was found that PEITC was equally effective as curcumin in isolation on inhibiting inflammation from the macrophage (measured by Nitric Oxide; IC80 of 5uM each) while SFN was more potent with an IC80 of 1uM; the synergism between PEITC and SFN at these concentrations was more potent than the synergism between SFN and Curcumin, and the combination with 40% of the concentration (2uM PEITC and 0.4uM SFN) was as effective as either alone at higher concentrations [48].

Mustard:

Glucoraphanin gets hydrolyzed by the myrosinase enzyme and then produces one of two metabolites, either 5-methylsulfinylpentane nitrile (via the ESP enzyme) or sulforaphane. While heating at low temperatures can enhance sulforaphane production from inactivating ESP [50] higher temperatures also inhibit myrosinase and prevent either metabolite from being formed.[51] Due to this balancing act (of which practical cooking techniques tend to denature myrosinase), the addition of mustard to the cooking of broccoli has been investigated as mustard (sinapsis alba) has a form of myrosinase that is much more heat resistant[52,53] whereas broccoli tends to have a heat sensitive form.[53,54] Due to this, when mustard seed powder is mixed with broccoli powder (1-2%; or 12-25mg per 250mg broccoli powder) the sulforaphane availability is increased when cooked, and the losses that would normally occur beyond 60°C instead occur above 90°C and cooking at a temperature that normally abolishes sulforaphane formation (8-12 minutes of boiling sous vide) has three-fold more sulforaphane when it is mixed with mustard seed [55].

The mixture of mustard seeds alongside broccoli powder during cooking can increase sulforaphane bioavailability since mustard has a more heat-resistant form of the enzyme that makes sulforaphane. That being said, the study mixed powders of both foods rather than cooking with the whole food products; this information may not apply to placing mustard seeds alongside broccoli florets.

References:

[1] https://www.ncbi.nlm.nih.gov/pubmed/20666718

[2] https://www.ncbi.nlm.nih.gov/pubmed/25804758/

[3] https://www.ncbi.nlm.nih.gov/pubmed/21434862

[4] https://www.ncbi.nlm.nih.gov/pubmed/24804252

[5] https://nanostilbene.com/?page_id=324

[6] https://www.ncbi.nlm.nih.gov/pubmed/25206336

[7] https://www.ncbi.nlm.nih.gov/pubmed/24496077

[8] https://www.ncbi.nlm.nih.gov/pubmed/22521481

[9] https://www.ncbi.nlm.nih.gov/pubmed/25699252

[10] https://www.ncbi.nlm.nih.gov/pubmed/25244368

[11] https://www.jstor.org/stable/3057437

[12] https://www.ncbi.nlm.nih.gov/pubmed/1549603

[13] https://www.ncbi.nlm.nih.gov/pubmed/10541453

[14] http://agris.fao.org/agris-search/search.do?recordID=US201301302101

[15] http://www.fupress.net/index.php/pm/article/view/1574

[16] http://www.plantphysiol.org/content/plantphysiol/early/2008/09/17/pp.108.126003.full.pdf

[17] https://www.ncbi.nlm.nih.gov/pubmed/25617536

[18] https://www.sciencedirect.com/science/article/pii/S0889157503000450

[19] https://www.ncbi.nlm.nih.gov/pubmed/16442570

[20] https://www.ncbi.nlm.nih.gov/pubmed/11410599
[21] https://www.ncbi.nlm.nih.gov/pubmed/16356123

[22] https://www.ncbi.nlm.nih.gov/pubmed/17115886

[23] https://www.ncbi.nlm.nih.gov/pubmed/7876079

[24] https://www.ncbi.nlm.nih.gov/pubmed/15728556

[25] https://www.ncbi.nlm.nih.gov/pubmed/20193003

[26] https://www.ncbi.nlm.nih.gov/pubmed/23072510

[27] https://www.ncbi.nlm.nih.gov/pubmed/17412634

[28] https://www.ncbi.nlm.nih.gov/pubmed/15313918

[29] https://www.ncbi.nlm.nih.gov/pubmed/21681606

[30] https://www.ncbi.nlm.nih.gov/pubmed/22005276

[31] https://www.ncbi.nlm.nih.gov/pubmed/15937340

[32] https://www.ncbi.nlm.nih.gov/pubmed/19805354

[33] https://www.ncbi.nlm.nih.gov/pubmed/16170022

[33] https://www.ncbi.nlm.nih.gov/pubmed/16280330

[35] https://www.ncbi.nlm.nih.gov/pubmed/23084523

[36] https://www.ncbi.nlm.nih.gov/pubmed/19584240

[37] https://www.ncbi.nlm.nih.gov/pubmed/22970326

[38] https://www.ncbi.nlm.nih.gov/pubmed/11836580

[39] https://www.ncbi.nlm.nih.gov/pubmed/22070051

[40] https://www.ncbi.nlm.nih.gov/pubmed/23050040

[41] https://www.ncbi.nlm.nih.gov/pubmed/23050040

[42] https://www.ncbi.nlm.nih.gov/pubmed/22957429

[43] https://www.ncbi.nlm.nih.gov/pubmed/23071780

[44] https://www.ncbi.nlm.nih.gov/pubmed/22025779

[45] https://www.ncbi.nlm.nih.gov/pubmed/18407246

[46] https://www.ncbi.nlm.nih.gov/pubmed/19913604

[47] https://www.ncbi.nlm.nih.gov/pubmed/22925073

[48] https://www.ncbi.nlm.nih.gov/pubmed/18841446

[49] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583628/

[50] https://www.ncbi.nlm.nih.gov/pubmed/15184012

[51] https://www.ncbi.nlm.nih.gov/pubmed/23109475

[52] https://www.sciencedirect.com/science/article/pii/S0308814605003341

[53] https://www.sciencedirect.com/science/article/pii/S0308814611013884

[54] https://www.ncbi.nlm.nih.gov/pubmed/10552454

[55] https://www.ncbi.nlm.nih.gov/pubmed/23411305


TSOI DD / NEWS / SS

Therapeutic Solutions International is focused on immune modulation
for the treatment of several specific diseases

http://therapeuticsolutionsint.com/


TSOI Is On the Right To Try (RTT) Pathway w/ new therapies and adjuvants for treatment, prevention, reduction , supression,  and increased survival of :
(Of the therapies / products listed below , some will be offered on the RTT pathway  , or could  be used in combination w/ other existing therapies , and therapeutics , or as a  monotherapy)

Stage 1 - 4 Cancers (Tumor types) Breast Cancer , Prostate Cancer  w/ StemVacs  Immunotherapy Platform https://stemvacs.com/ , BRS-001 http://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/77635806/therapeutic-solutions-international-expands-adopti  , and  NanoStilbeneTM , http://mynanostilbene.com/
Cancer Metabolic DeTox,  https://www.globenewswire.com/news-release/2017/05/09/1076506/0/en/Therapeutic-Solutions-files-new-Patent-on-Targeting-the-Tumor-Microenvironment-through-Nutraceutical-Based-Immunoadjuvants.html
and IsoStilbene https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/77734511/therapeutic-solutions-international-releases-isos
Liver Cancer, Esophageal Cancer, Melanoma (w/ Ipilimumab)
and NanoStilbeneTM   http://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/80371866/therapeutic-solutions-international-reports-its-na

Breast Cancer, Prostate Cancer,
and Ovarian Cancer w/ Ozone therapy , and NanoStilbene  https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/78060284/therapeutic-solutions-international-reports-synerg

Prostate Cancer
w/ Nano PSA https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/80285424/therapeutic-solutions-international-develops-gluco
and Nano Myros  https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/80311774/therapeutic-solutions-international-develops-adjuv

Glioma / Brain Cancers https://therapeuticsolutionsint.com/?page_id=232 w/ NeuroStilbene , and Brain Cancer Therapeutics  https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/77868683/therapeutic-solutions-international-inc-release

CTE / Military and Sports Brain Injuries - (Chronic Traumatic Encephalopathy) w/ JadiCell MSCs (Mesenchymal Stem Cells) https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/80242706/therapeutic-solutions-international-obtains-exclus ,
Autologous Neurogenic Stem Cell Bankinghttp://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/79022244/therapeutic-solutions-international-continues-to-e
sRNA augmented stem cells
, http://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/78834511/therapeutic-solutions-international-expands-chroni
"Educated" Monocytes / Progenitors
https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/79095195/therapeutic-solutions-international-continues-to-e
and NeuroStilbene http://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/78538984/therapeutic-solutions-international-announces-cte

TBI / mTBI - (Traumatic Brain Injury / mild TBI) w/ JadiCell MSCs, https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/80242706/therapeutic-solutions-international-obtains-exclus
and NeuroStilbene https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/77868683/therapeutic-solutions-international-inc-release

Neutropenia (Low white blood cell count) w/ NanoStilbene
https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/80689184/therapeutic-solutions-international-reports-nanost

CRS - (Cytokine Release Syndrome) / InflammationCar-T sickness /  Immunotherapy side effects  w/ NanoStilbeneTM  https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/78326088/therapeutic-solutions-international-files-patent-o
 
Diabetes, Cardiovascular Disease, and Neurodegenerative Diseases
w/ Projuvenol ® https://www.biomedreports.com/market-wire/259588-therapeutic-solutions-international-files-patent-covering-projuvenol(c)-and-its-active-ingredient-pterostilbene.html

Neurodegenerative Conditions / Oxidative Brain and Neural Disorders  MS (
Multiple Sclerosis), Stroke / post Stroke recovery, and Alzheimers w/ Alpha Lipoic Acid https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/78013140/therapeutic-solutions-international-develops-micro

Elevated PSA Levels  w/ Nano PSA https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/80285424/therapeutic-solutions-international-develops-gluco
and Nano Myros https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/80311774/therapeutic-solutions-international-develops-adjuv

RA
- (Rheumatoid Arthritis) Synovitis w/ Nano PSA https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/80285424/therapeutic-solutions-international-develops-gluco
and Nano Myros https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/80311774/therapeutic-solutions-international-develops-adjuv

TNF (Tumor Necrosis Factor) / Atherosclerosis / TF (Tissue Factor) ElevationsSepsis, Cardiovascular Disease, RA , Infectionand Trauma w/  NanoStilbene PKE  https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/79295986/therapeutic-solutions-international-continues-to-r

MRSA , UVB radiation-induced skin damage
and carcinogenesis w/ DermalStilbene  https://www.globenewswire.com/news-release/2018/05/21/1509405/0/en/Therapeutic-Solutions-International-Releases-DermalStilbene-a-Topical-Formulation-of-Pterostilbene.html


TSOI Right to Try

San Diego County physician to challenge Democratic Rep. Scott ...

Therapeutic Solutions International Announces the Appointment of
James Veltmeyer, MD as Chief Medical Officer

https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/77684969/therapeutic-solutions-international-announces-the

Oceanside, CA -- June 18, 2018 -- InvestorsHub NewsWire -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) previously announced their plans to provide access to its clinical stage cancer immunotherapy product StemVacs under the Right To Try law signed by President Trump on May 30th 2018, and have appointed Dr. James Veltmeyer as Chief Medical Officer of their future planned cancer clinic.

"Having Dr. Veltmeyer head up our future "Right To Try Cancer Clinic", as well as all other clinical programs underway is a dream come true for TSOI," said Timothy Dixon, President, and CEO of Therapeutic Solutions International. "In his role as Chief of the Department of Family Medicine at Sharp Grossmont Hospital, where he currently provides senior leadership to over 200 physicians, Dr. Veltmeyer has developed skills that few ever do, allowing him to bring a wealth of experience in management and medicine to bear on our programs.

FDA Right to Try info for patients
https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/right-try

The Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act, or Right to Try Act, was signed into law May 30, 2018. This law is another way for patients who have been diagnosed with life-threatening diseases or conditions who have tried all approved treatment options and who are unable to participate in a clinical trial to access certain unapproved treatments.

Clinical trials provide information about whether a product is safe to use and can effectively treat or prevent a disease. People may have many reasons for participating in clinical trials. In addition to contributing to medical knowledge, some people participate in clinical trials because there is no treatment for their disease, treatments they tried have not worked, or they are not able to tolerate the current treatments.

For patients with serious or immediately life-threatening diseases or conditions, the FDA remains committed to enhancing access to promising investigational medicines for those unable to access investigational medical products through clinical trials. This is the mission of our expanded access program. The agency is dedicated to these purposes, and it has been for more than three decades.

Building on our long-standing efforts to help patients and families who are facing life-threatening diseases or conditions, the FDA is providing information for patients on the Right to Try Act. FDA’s role in implementation of the Right to Try Act is largely focused on those obligations outlined in the law, which is limited to receipt and posting of certain information submitted regarding Right to Try use.

The Right to Try Act permits/allows eligible patients to have access to eligible investigational drugs.

An eligible patient is a patient who has:

  • Been diagnosed with a life-threatening disease or condition
    Exhausted approved treatment options and is unable to participate in a clinical trial involving the eligible investigational drug (this must be certified by a physician who is in good standing with their licensing organization or board and who will not be compensated directly by the manufacturer for certifying)
    And has provided, or their legally authorized representative has provided, written informed consent regarding the eligible investigational drug to the treating physician

An eligible investigational drug is an investigational drug:

  • For which a Phase 1 clinical trial has been completed
    That has not been approved or licensed by the FDA for any use
    For which an application has been filed with the FDA or is under investigation in a clinical trial that is intended to form the primary basis of a claim of effectiveness in support of FDA approval and is the subject of an active investigational new drug application submitted to the FDA
    Whose active development or production is ongoing, and that has not been discontinued by the manufacturer or placed on clinical hold by the FDA

Who is in charge of pre-approval access decisions ?
https://med.nyu.edu/departments-institutes/population-health/divisions-sections-centers/medical-ethics/research/working-group-compassionate-use-preapproval-access/frequently-asked-questions#what-is-the-federal-right-to-try-law

 The companies developing new medical products are the key decision-makers in determining whether to provide access to their investigational medical products. This is the case for both expanded access and right to try. Furthermore, companies that are willing to provide investigational products get to decide which pathway they’ll use. For example, a physician may seek access to a drug via right to try, but the company may inform the physician that it will provide it only via expanded access pathway, or vice versa

“Right to try” is restricted to patients with life-threatening diseases or conditions, as defined by the Code of Federal Regulations (CFR) Title 21, Part 312.81: (1) diseases or conditions where the likelihood of death is high unless the course of disease is interrupted; and (2) diseases or conditions with potentially fatal outcomes, where the end point of clinical trial analysis is survival.

Currently, CUPA is aware of only one company that has opted to make its investigational products available via right to try. Therapeutic Solutions International has indicated its willingness to provide an investigational (post–phase I) stem cell immunotherapy product to oncology patients.


Therapeutic Solutions International Collaborates with Right to Try Foundation on Novel Means of Protecting Patients While Hyper-accelerating Drug Development
http://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/80471558/therapeutic-solutions-international-collaborates-w


OCEANSIDE, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) -- via NetworkWire – Therapeutics Solutions International, Inc., (OTC Markets: TSOI) together with The Right to Try Foundation announced filing of a patent covering its proprietary method of implementing S.204, the Trickett Wendler, Frank Mongiello, Jordan McLinn and Matthew Bellina Right to Try Act in a manner which provides a novel means of safeguarding patients while allowing rapid access to experimental medications.

The patent application is based on the current Standard Operating Procedures of the Right to Try Foundation, which call for a physical or virtual independent Institutional Review Board assessment of each patient considered for an experimental medication.

"The fact that publicly this new pathway of providing hope to patients with no hope has only been used two times [1] since the law was passed is appalling" said Famela Ramos, President and Founder of the Right to Try Foundation. "Why are American patients with terminal illnesses travelling to hospitals outside the USA when so many experimental treatments are available here? By establishing an independent means of ensuring patients are protected, we believe that we solve the issue that many opponents of the law raise, which is that patients will be victims of predatory companies."

The Right to Try Foundation seeks to accelerate medical progress by establishing means by which drugs that are demonstrated safe can be used for different diseases or in combinations with other drugs based on the ideas of the doctors and not the Pharmaceutical Companies.

Therapeutic Solutions International has a filed Investigational New Drug (IND) application for StemVacs™ a novel Cell Based Cancer Immunotherapy [2] that specifically trains the immune system to kill cancer stem cells.

"Immunotherapy is the greatest advancement in the area of clinical oncology," said James Veltmeyer, MD, Chief Medical Officer of Therapeutic Solutions International. "To our knowledge, StemVacs™ is the only clinical stage immunotherapeutic that kills cancer stem cells. This, combined with the safety and signals of efficacy obtained from the current Phase 1 clinical trial, support us to expand the use of StemVacs™ under President Trump's recently passed Right to Try Law. I applaud Timothy Dixon and Famela Ramos for this joint collaboration leading to a new pathway to take drugs into the clinic with an added level of safety."

"We have highly benefitted from working with the Right to Try Foundation in terms of establishing necessary procedures and systems to not only utilize this new law but to collect data in a Good Clinical Practices compliant manner, said Timothy Dixon, President and CEO of Therapeutics Solutions International. "Our Phase I safety data motivates us to continue clinical development of StemVacs™, of which part of the development pathway absolutely includes providing patients access to it now under the Right to Try Law and we are very excited to continue our work with Right To Try Foundation."
 

TSOI CEO Tim G Dixon receiving the Right To Try Leadership Award (Video) 12/19/18
https://www.facebook.com/tsoihome/videos/2083466298358398/


TSOI R&D

TSOI Patent Portfolio  https://therapeuticsolutionsint.com/?page_id=68
TSOI Scientific Advisory Board  https://therapeuticsolutionsint.com/?page_id=64

TSOI Products

8 Biologics, 18 Nutraceuticals, 1 Pharmaceutical = 27



8 Biologics
StemVacs
http://stemvacs.com/
innaMune http://www.marketwired.com/press-release/therapeutic-solutions-files-patent-on-blood-derived-innate-immune-system-stimulator-otc-pink-tsoi-2216672.htm
MemoryMune http://www.marketwired.com/press-release/therapeutic-solutions-files-patent-on-methods-re-activating-dormant-memory-cells-with-otc-pink-tsoi-2220094.htm
BRS-001 http://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/77635806/therapeutic-solutions-international-expands-adopti
sRNA augmented stem cells http://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/78834511/therapeutic-solutions-international-expands-chroni
JadiCell MSCs https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/78853508/therapeutic-solutions-international-signs-agreemen
Autologous Neurogenic Stem Cell banking http://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/79022244/therapeutic-solutions-international-continues-to-e
"Educated" Monocytes / Projenitors https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/79095195/therapeutic-solutions-international-continues-to-e
Image result for NanoStilbene
 
18 Nutraceuticals
 (12 below + 7 distributed by Immun ET Labs = 19 -1  for duplicate Nano-Cannabidiol formulations offered by TSOI and Immun ET Labs = 18)
Projuvenol http://projuvenol.com/
NanoStilbene PKE http://mynanostilbene.com/
DermalStilbene http://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/77477228/therapeutic-solutions-international-releases-derm
NanoPlus http://www.youcanordernow.com/NanoPlus-12ml-wgraduated-glass-eyedropper_p_29.html
Nano Cannabidiol http://www.youcanordernow.com/Nano-Cannabidiol-12ml-w-glass-eyedropper_p_30.html

Image may contain: drinkImage result for NeuroStilbene

IsoStilbene https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/77734511/therapeutic-solutions-international-releases-isos
NeuroStilbene https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/77868683/therapeutic-solutions-international-inc-release
Alpha Lipoic Acid https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/78013140/therapeutic-solutions-international-develops-micro
Cancer Metabolic DeTox http://www.marketwired.com/press-release/therapeutic-solutions-files-new-patent-on-targeting-tumor-microenvironment-through-nutraceutical-otc-pink-tsoi-2215015.htm

No photo description available.

Nano PSA https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/80285424/therapeutic-solutions-international-develops-gluco?_ga=2.179046118.372974125.1561310240-1993038973.1559041875
Nano Myros https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/80311774/therapeutic-solutions-international-develops-adjuv
Nano Myros w/ Cannabidiol http://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/80328380/therapeutic-solutions-international-adds-nano-cann


Therapeutic Solutions International Awards Distribution of NanoStilbene and Nano Cannabidiol in Mexico to Immun ET Laboratories, LLC.
https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/79840011/therapeutic-solutions-international-awards-distrib

Image may contain: drink
 
7 Products currently offered under the Immun ET Label :
https://immhealth.com/products?olsPage=products

IMM NanoStilbene https://immhealth.com/products?olsPage=products%2Fimm-nanostilbene
IMM NanoVita https://immhealth.com/products?olsPage=products%2Fimm-nanovita
IMM NanoVita Plus https://immhealth.com/products?olsPage=products%2Fimm-nanovitaplus

IMM NanoStilbene Topical Relief Spray https://immhealth.com/products?olsPage=products%2Fimm-nanostilbene-topical-relief-spray
IMM NanoStilbene Intranasal Spray https://immhealth.com/products?olsPage=products%2Fimm-nanostilbene-intranasal-spray
IMM Nano Cannabidiol https://immhealth.com/products?olsPage=products%2Fimm-nanocannabidiol

IMM Corporal Cream https://immhealth.com/products?olsPage=products%2Fcorporal-cream

1 Pharmaceutical
LymphoBoost http://www.marketwired.com/press-release/therapeutic-solutions-files-new-patent-on-augmentation-anti-tumor-immunity-mifepristone-otc-pink-tsoi-2217703.htm

6  Products currently offered on TSOI E Commerce Site :
Projuvenol, NanoStilbene PKE, DermalStilbene, NanoPlus, Nano Cannabidiol, NanoPSA

http://www.youcanordernow.com/

4 Biologics, 3 Nutraceuticals, 1 Pharmaceutical licensed to Pan Am Cancer Treatment Center in Mexico
StemVacs, innaMune, MemoryMune, BRS-001, Cancer Metabolic DeTox, NanoStilbene, IsoStilbene, LymphoBoost


http://ih.advfn.com/p.php?pid=nmona&article=77606645
http://ih.advfn.com/p.php?pid=nmona&article=77309980
http://ih.advfn.com/p.php?pid=nmona&article=77635806
https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/77734511/therapeutic-solutions-international-releases-isos


Pan Am Cancer Treatment Center Introductory Tour Video
https://www.youtube.com/watch?v=rWgJLRCICa8&feature=youtu.be

TSOI Products in Development
https://www.facebook.com/tsoihome/photos/a.842637622429432/2740350235991485/?type=3&theater
 Look for many new exciting specialty products to come from these facilities including combination compounds such as pterostilbene and cannabidiol, pterostilbene and alpha-lipoic-acid, pterostilbene and huperzine, all in nanoparticle formulations.





NEWS 9/9/19
Therapeutic Solutions International Reports NanoStilbene™ Protects the Immune System
from Cancer Chemotherapy
Newly Discovered Properties of NanoStilbene Potentially Allows Company to Address
$3.9 Billion Chemotherapy Induced Neutropenia Market

https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/80689184/therapeutic-solutions-international-reports-nanost

OCEANSIDE, CA -- September 9, 2019 -- InvestorsHub NewsWire -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today new data and the filing of a patent application covering the ability of NanoStilbene™ [1] and its active ingredient, pterostilbene, at accelerating recovery of blood cells after treatment with chemotherapy.

Neutropenia is an abnormally low number of neutrophils (a type of white blood cell) in the blood. Neutropenia, if severe, significantly increases the risk of life-threatening infection. Neutropenia is often a side effect of the treatment of cancer with chemotherapy or radiation therapy.

In animals treated with the chemotherapeutic agent 5-fluorouracil, recovery of white blood cells occurred significantly faster in animals that also received NanoStilbene™ as compared to animals that received a placebo. The results were replicated with other types of chemotherapy including high dose cyclophosphamide and busulfan.

"We have previously reported that NanoStilbene™ can synergize with low dose cyclophosphamide at increasing immune response and killing of cancer [2]" said Dr. James Veltmeyer, Chief Medical Officer of the Company. "This new data supports the possibility of using NanoStilbene™ in many cancer patients who are taking chemotherapy, in order to protect the patients from the side effects of chemotherapy. In many cases, patients receiving chemotherapy have reduced white blood cells, which causes various types of infectious disease."

Currently, drugs such as Neulasta™ and Neupogen™ are used for increasing white blood cells in cancer patients taking chemotherapy. Unfortunately, these drugs cannot be taken prophylactically, and are highly expensive. According to Fierce Pharma, Neulasta™ had sales of $3.8 billion in 2018 [3]. More importantly, NanoStilbene possesses direct cancer-inhibitory properties, meaning that potentially it not only prevents chemotherapy-associated side effects but also increases the activity of the chemotherapy to kill cancer.

"I am impressed by the wide spectrum activity of the NanoStilbene™ product. It is very rare to find a therapy that concurrently suppresses the growth of cancer, stimulates the immune system, and protects the bone marrow from chemotherapy-induced toxicity" said Dr. Feng Lin, Chief Scientific Officer of the Company. "Since NanoStilbene™ is already on the market as a nutraceutical, I anticipate it will rapidly be utilized by informed patients who are suffering from cancer."

NanoStilbene is a nanoemulsion of nanoparticle pterostilbene in the range of 75-100nm at a concentration of 200mg per milliliter. Nanoparticle therapeutics is an emerging treatment modality for cancer and other inflammatory disorders. The National Cancer Institute has recognized nanotechnology as an emerging field with the potential to revolutionize modern medicine for the detection, treatment, and prevention of cancer.

"This Company was founded not only to advance great science but more importantly, to help patients for which limited options exist. The development of NanoStilbene™, we believe, offers the potential of a new generation of non-toxic compounds that concurrently stimulate the immune system while suppressing cancer at the same time" said Timothy Dixon, President, and CEO of the Company.

About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one's immune system. The Company's corporate website is www.therapeuticsolutionsint.com and e-commerce at www.youcanordernow.com.

[1] https://mynanostilbene.com/?page_id=159
[2] https://www.globenewswire.com/news-release/2019/07/29/1892915/0/en/NanoStilbene-Nutraceutical-Shown-to-Increase-Ability-of-Cyclophosphamide-Chemotherapy-to-Suppress-Cancer.html
[3] https://www.fiercepharma.com/special-report/9-neulasta

NEWS 9/3/19
Feng Lin, MD, Ph.D., Joins Therapeutic Solutions International as Chief Scientific Officer
Immuno-Oncology Nutraceutical Company Positions Itself for Expansion into FDA


http://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/80650612/feng-lin-md-ph-d-joins-therapeutic-solutions-i

NEWS 8/29/19
Therapeutic Solutions International, Inc. Reports Revenues Up 850% for Q2 and 850% for 1st 6 months

https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/80626982/therapeutic-solutions-international-inc-reports

NEWS 8/26/19 Therapeutic Solutions International Announces Positive Clinical Data Using NanoStilbene™ to Stimulate Immune System in Advanced Cancer Patients
Company Submits Results of Clinical Trial for Publication in Peer Reviewed Medical Journal

https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/80602113/therapeutic-solutions-international-announces-posi

NEWS 8/5/19
Therapeutic Solutions International Collaborates with Right to Try Foundation on Novel Means of Protecting Patients While Hyper-accelerating Drug Development
Company Plans to Advance its Phase I Cancer Immunotherapy StemVacs™ to US Patients

https://www.globenewswire.com/news-release/2019/08/05/1896899/0/en/Therapeutic-Solutions-International-Collaborates-with-Right-to-Try-Foundation-on-Novel-Means-of-Protecting-Patients-While-Hyper-accelerating-Drug-Development.html

NEWS 7/29/19
NanoStilbene™ Nutraceutical Shown to Increase Ability of Cyclophosphamide Chemotherapy to Suppress Cancer
Recent Data Supports Investigation of Commercially Available Product
as an Adjuvant to Chemotherapy for Cancer

https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/80417735/nanostilbene-8482-nutraceutical-shown-to-increas

NEWS 7/22/19
Therapeutic Solutions International Reports its NanoStilbene™ Nutraceutical Product Enhances Efficacy of FDA Cleared Cancer Immunotherapy in Animal Model of Cancer
New Data Supports Development of Patented Formulation of Blueberry Extract Pterostilbene as an Adjuvant to Immuno-Oncology Treatments

https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/80371866/therapeutic-solutions-international-reports-its-na

NEWS 7/15/19
Therapeutic Solutions International adds Nano Cannabidiol to NanoMyros for Inhibition of Microvesicle and Exosome Release in Prostate Cancer
https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/80328380/therapeutic-solutions-international-adds-nano-cann

NEWS 7/11/19
Therapeutic Solutions International Develops Adjuvant Technology to Enhance Prostate Cancer Suppressing Properties of NanoPSA
Company Reports Synergistic Activation of Anti-Cancer Protein NRF2 By Proprietary Combination Approach

https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/80311774/therapeutic-solutions-international-develops-adjuv

NEWS 7/8/19
Therapeutic Solutions International Develops Glucoraphanin + NanoStilbene Encapsulated product for reduction of Prostate Specific Antigen (PSA)
https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/80285424/therapeutic-solutions-international-develops-gluco

NEWS 7/1/19 
Therapeutic Solutions International Obtains Exclusive License for Patented Clinical Stage Adult Stem Cell for Treatment of Military and Sports Brain Injuries

https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/80242706/therapeutic-solutions-international-obtains-exclus

NEWS 5/6/19
Therapeutic Solutions International Awards Distribution of NanoStilbene and Nano Cannabidiol in Mexico to Immun ET Laboratories, LLC.
NanoStilbene Shown to Enhance Anticancer Immunity in Cancer Patients through Modulation of Inflammatory Mediators

https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/79840011/therapeutic-solutions-international-awards-distrib

NEWS 2/19/19
Therapeutic Solutions International Continues to Refine NanoStilbene™ Formulation

NanoStilbene Shown to Reduce Tumor Necrosis Factor-a (TNF-a ) in Cancer Patients
https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/79295986/therapeutic-solutions-international-continues-to-r

TSOI News History 5/1/18 - 1/22/19
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146277441


SHARE STRUCTURE
https://www.otcmarkets.com/stock/TSOI/security

AS - 2.5 B common , 5 M preferred - https://www.nvsos.gov/SOSEntitySearch/CorpDetails.aspx?lx8nvq=LvtIoYTPV6wB1RIovm008A%253d%253d&nt7=0
OS - 1,412,391,182
Restricted - 1,003,510,972
Unrestricted - 348,846,877
Held at DTC - 303,593,877
Float - 303,593,877


SEC Filings https://www.sec.gov/cgi-bin/browse-edgar?company=therapeutic+solutions+international&match=contains&action=getcompany

TA
New Horizon Transfer Inc.
215-515 West Pender Street
Vancouver, BC V6B 6H5
CAN(604) 876-5526
http://newhorizontransfer.com/

TSOI Management
https://therapeuticsolutionsint.com/?page_id=62

Contact
Investor Relations
ir@tsoimail.com

Corporate Website
http://therapeuticsolutionsint.com/
Additional info
http://projuvenol.com/
http://mynanostilbene.com/
https://stemvacs.com/

E Commerce Sites
http://www.youcanordernow.com/
http://immhealth.com/?route=common/home&home_id=44

TSOI Facebook
https://www.facebook.com/tsoihome/
TSOI Twitter
https://twitter.com/tsoisupplement
https://twitter.com/search?f=tweets&vertical=default&q=%24TSOI&src=typd

https://twitter.com/hashtag/NanoStilbene?src=hash
Disclaimer : All of the information presented in the IBOX , Stickies , or posts on this board , is based on individual opinions , and is not to be considered as a recommendation to buy , sell , or hold this stock .

 

TSOI
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
TSOI News: Current Report Filing (8-k) 10/09/2019 12:59:28 PM
TSOI News: Therapeutic Solutions International Reports NanoStilbene™ Protects the Immune System from Cancer Chemotherapy 09/09/2019 09:00:00 AM
TSOI News: Feng Lin, MD, Ph.D., Joins Therapeutic Solutions International as Chief Scientific Officer 09/03/2019 09:00:00 AM
TSOI News: Therapeutic Solutions International, Inc. Reports Revenues Up 850% for Q2 and 850% for 1st 6 months 08/29/2019 09:00:00 AM
TSOI News: Therapeutic Solutions International Announces Positive Clinical Data Using NanoStilbene™ to Stimulate Immune System 08/26/2019 09:00:00 AM
PostSubject
#12500  Sticky Note TSOI DD centsability4me 10/14/19 06:35:29 AM
#12276  Sticky Note Gm all TSOI news Therapeutic Solutions International Reports sharky 09/09/19 09:07:41 AM
#11515  Sticky Note NanoStilbeneā„¢ Nutraceutical Shown to Increase Ability of Cyclophosphamide centsability4me 07/30/19 12:38:47 PM
#10881  Sticky Note TSOI wins leadership award, Right to Try.. TruthFairy222 07/22/19 12:27:03 PM
#12524   At this stage i am guessing what could ADVFN_curncman 10/21/19 09:59:46 AM
#12523   What will make the Market Cap skyrocket? rrao11 10/21/19 09:44:43 AM
#12522   I would seriously consider investing in this ADVFN_curncman 10/21/19 08:54:39 AM
#12521   Add this to your DD file everyone: centsability4me 10/19/19 11:27:33 AM
#12520   I have not taken position in TSOI but ADVFN_curncman 10/18/19 10:14:15 AM
#12519   we just wait and see what it will Tonneke 10/18/19 10:09:22 AM
#12518   Once TSOI becomes noticed by many momentum traders ADVFN_curncman 10/18/19 10:05:49 AM
#12517   I am not pesimistic but the holes for Tonneke 10/18/19 09:31:04 AM
#12516   There is something BIG we are waiting to ADVFN_curncman 10/17/19 02:24:41 PM
#12515   Re: Nano PSA centsability4me 10/17/19 12:58:30 PM
#12514   NanoPSA on TSOI E-Commerce site centsability4me 10/17/19 09:11:49 AM
#12513   If history repeats itself we should see some whitehotcoal 10/17/19 07:52:33 AM
#12512   usually before a strong rise, they make one corvatsch 10/16/19 02:02:12 PM
#12511   This could be it!!! Go time??!! BillTheTrader 10/16/19 01:25:30 PM
#12510   Thank you so much for all the information Yooperman 10/16/19 08:26:37 AM
#12509   haha what a nice game, I almost bet Tonneke 10/15/19 02:35:08 PM
#12508   Take out that 700k at .0017 and we BillTheTrader 10/15/19 11:01:15 AM
#12507   so everyone knows now that TSOI centsability4me 10/15/19 09:01:26 AM
#12505   I am posting this article centsability4me 10/15/19 08:29:48 AM
#12504   you are one of the first to mention centsability4me 10/14/19 08:05:22 AM
#12503   TSOI makes the drug with bio molecules (no ADVFN_curncman 10/14/19 06:51:19 AM
#12502   I have a feeling that the next news ADVFN_curncman 10/14/19 06:46:41 AM
#12501   Cents4Stability, hope some buyback and retirement of shares ADVFN_curncman 10/14/19 06:37:36 AM
#12500   TSOI DD centsability4me 10/14/19 06:35:29 AM
#12499   favorable :) centsability4me 10/13/19 02:52:42 PM
#12498   centstability4me, I have read up on the RTT ADVFN_curncman 10/13/19 01:54:20 PM
#12497   "We are honored to have such an accomplished centsability4me 10/13/19 12:31:50 PM
#12496   27 products total centsability4me 10/13/19 11:37:29 AM
#12495   Cents You said they have 21 products already. ADVFN_curncman 10/13/19 10:53:34 AM
#12494   Looking like things are starting to move forward BillTheTrader 10/13/19 09:41:38 AM
#12493   Nano PSA Sequence photos on TSOI Facebook centsability4me 10/13/19 08:56:36 AM
#12492   yes centsability4me 10/12/19 12:56:05 PM
#12491   Centsstability4me, fantastic progress and new neutraceutical compound discovered ADVFN_curncman 10/12/19 12:45:41 PM
#12490   IBOX update centsability4me 10/12/19 12:24:43 PM
#12489   TSOI Well worth the wait JackAskSlap 10/11/19 06:16:23 PM
#12488   nice message Tonneke 10/11/19 06:14:17 PM
#12487   We hope to have the NanoPSA (glucoraphanin + centsability4me 10/11/19 05:19:29 PM
#12486   Walter White: Do you want to cook? corvatsch 10/11/19 02:22:17 PM
#12485   Sometimes, when we're very quiet it's because we're corvatsch 10/11/19 02:20:04 PM
#12484   I had seen them, such a nice message Tonneke 10/11/19 09:14:06 AM
#12483   New photos of TSOI labs centsability4me 10/11/19 08:05:04 AM
#12482   haha and yet again sneaky 0.0001 or 0.0002 off Tonneke 10/10/19 02:06:51 PM
#12481   All these gifts and no one is buying them. BillTheTrader 10/10/19 02:05:55 PM
#12480   Great day so far. Moving on up!! BillTheTrader 10/10/19 01:46:13 PM
#12479   TSOI NEWS History centsability4me 10/10/19 08:16:54 AM
#12478   SHARE STRUCTURE centsability4me 10/10/19 08:09:37 AM
#12477   I believe it will be okay with the Tonneke 10/10/19 07:50:26 AM
#12476   .. not a bad sign either. Gerry is Shel_SWFL 10/09/19 02:56:31 PM
#12475   ? abazaba375 10/09/19 02:48:48 PM
#12474   Not a good sign BillTheTrader 10/09/19 01:50:47 PM
PostSubject